The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date; safety profile of sotatercept consistent with previous studies and efficacy improvements maintained after one year of therapy
Exploratory post-hoc analysis of STELLAR shows potential of sotatercept to improve cardiovascular function
Interim results from SOTERIA open-label extension study represent longest safety and.